Table 3.
Regression results for screening risk variables
| Odds ratio (95% CI) | P value | P adjust | E-value | |
|---|---|---|---|---|
| Demographics | ||||
| Sex | ||||
| Male | [Reference] | |||
| Female | 0.69 (0.33–1.44) | 0.323 | 0.420 | 1.69 |
| Age | 0.98 (0.95–1.01) | 0.231 | 0.334 | 1.11 |
| csDMARDs | ||||
| Treated with csDMARDs | ||||
| N | [Reference] | |||
| Y | 0.77 (0.29–2.09) | 0.611 | 0.611 | 1.53 |
| Treated with Iguratimod | ||||
| N | [Reference] | |||
| Y | 1.46 (0.52–4.02) | 0.469 | 0.508 | 1.71 |
| Drug adjustment | ||||
| Glucocorticoid taper | ||||
| N | [Reference] | |||
| Y | 2.61 (1.38–4.92) | 0.003 | 0.010 | 2.61 |
| csDMARDs taper | ||||
| N | [Reference] | |||
| Y | 2.97 (1.90–4.64) | < 0.001 | < 0.001 | 2.84 |
| Adverse reactions | ||||
| Number of symptoms | 1.24 (1.08–1.42) | 0.002 | 0.008 | 1.47 |
| Psychological health surveys | ||||
| FACIT-F | 0.95 (0.93–0.96) | < 0.001 | < 0.001 | 1.19 |
| PHQ-9 | 1.06 (0.99–1.12) | 0.074 | 0.120 | 1.20 |
| GAD-7 | 1.07 (1.02–1.13) | 0.004 | 0.010 | 1.23 |
| PSQI | 1.06 (1.00–1.13) | 0.060 | 0.112 | 1.21 |
| Health status score | ||||
| Patient self-report outcome (previous infection) | 1.06 (0.92–1.22) | 0.447 | 0.528 | 1.20 |
| Patient self-report outcome (current) | 0.87 (0.76–0.99) | 0.041 | 0.089 | 1.35 |
P-adjusted values are determined using the Benjamini-Hochberg (BH) correction method. The E-value measures the minimal magnitude of an association necessary, similar in scale to the observed effect size, for a potential confounding variable to explain the observed association